The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
Parminder K. Judge(University of Oxford), William G. Herrington(Oxford Health NHS Foundation Trust), Jennifer B. Green, Ryoki Arimoto(University of Oxford), Natalie Staplin(University of Oxford), Colin Baigent(University of Oxford), Christoph Wanner(Universitätsklinikum Würzburg), Masaomi Nangaku(The University of Tokyo), Katherine R. Tuttle(Providence Regional Medical Center Everett), Shimoli Shah(Boehringer Ingelheim (Germany)), Kaitlin J. Mayne, Emily Sammons(University of Oxford), Doreen Zhu, Martin Landray(Gentofte Hospital), Peter Rossing(Steno Diabetes Centers), Sibylle J. Hauske(Heidelberg University), Richard Haynes, Nikita Agrawal(University of Oxford), Martina Brueckmann(Boehringer Ingelheim (Germany)), Rebecca J. Sardell(University of Miami), Lisa Cronin(Boehringer Ingelheim (Germany))
Cited by 66
Related Papers
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k